HIV-1 drug resistance patterns among treatment-naïve and therapy-experienced patients in Poland

HIV and AIDS Review

Volumn 6, Issue 1, 2007, Pages 32-36

  Stańczak, Grzeorz P ^a   Stanczak J J ^a   Majchrzak, M J ^a   Burkacka, E ^a   Wiercinska Drapalo A ^b   Leszczyszyn Pynka, M ^c   Jablonowska E ^d   Malolepsza E ^d   Horban, A ^a  

^a SP ZOZ Wojewodzki Szpital Zakazny Centrum Diagnostyki i Terapii AIDS Warszawa   (Poland)

^b MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^c POMERANIAN MEDICAL UNIVERSITY   (Poland)

^d MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

HIV 1 drug resistance; Therapy experienced; Therapy naive

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; CD4 CD8 RATIO; CONTROLLED STUDY; DISEASE CLASSIFICATION; ELECTROPHORESIS; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; MAJOR CLINICAL STUDY; MALE; POLAND; RETROSPECTIVE STUDY; SALVAGE THERAPY; SEQUENCE ANALYSIS; VIRUS IDENTIFICATION; VIRUS LOAD; VIRUS MUTATION; VIRUS RESISTANCE; VIRUS STRAIN;

EID: 38049067606     PISSN: 17301270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1730-1270(10)60040-9     Document Type: Article

References (25)

1. Mocroft A, Phillips AN, Soriano V, Rockstroh J, Blaxhult A, Katlama C Phillips AN, Lundgren JD; EuroSIDA Study Group. Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection. AIDS Res Hum Retroviruses. 2005;21:527-36.
2. Wensing AM, van de Vijver DA, Angarano G, Asjo B, Balotta C, Boeri E Camacho R, Chaix ML, Costagliola D, De Luca A, Derdelinckx I, Grossman Z, Hamouda O, Hatzakis A, Hemmer R, Hoepelman A, Horban A, Korn K, Kucherer C, Leitner T, Loveday C, MacRae E, Maljkovic I, de Mendoza C, Meyer L, Nielsen C, Op de Coul EL, Ormaasen V, Paraskevis D, Perrin L, Puchhammer-Stockl E, Ruiz L, Salminen M, Schmit JC, Schneider F, Schuurman R, Soriano V, Stanczak G, Stanojevic M, Vandamme AM, Van Laethem K, Violin M, Wilbe K, Yerly S, Zazzi M, Boucher CA; SPREAD Programme. Prevalence of Drug-Resistant HIV-1 Variants in Untreated Individuals in Europe: Implications for Clinical Management. J Infect Dis. 2005;192:958-66
3. Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC Koup RA, Mellors JW, Connick E, Conway B, Kilby M, Wang L, Whitcomb JM, Hellmann NS, Richman DD. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med. 2002;347:385-94
4. Escoto-Delgadillo M, Vazquez-Valls E, Ramirez-Rodriguez M, Corona-Nakamura A, Amaya-Tapia G, Quintero-Perez N, Panduro-Cerda A, Torres-Mendoza BM. Drug-resistance mutations in antiretroviral-naive patients with established HIV-1 infection in Mexico. HIV Med. 2005;6:403-9.
5. Ammaranond P, Cunningham P, Oelrichs R, Suzuki K, Harris C, Leas L, Grulich A, Cooper DA, Kelleher AD. Rates of transmission of antiretroviral drug resistant strains of HIV-1. J Clin Virol. 2003;26:153-61.
6. EACS Euroguidelines Group. European guidelines for the clinical management and treatment of HIV-infected adults in Europe. AIDS 2003; 17 (suppl 2): S3-26
7. Derdelinckx I, Van Laethem K, Maes B, Schrooten Y, De Wit S, Florence E Fransen K, Ribas SG, Marissens D, Moutschen M, Vaira D, Zissis G, Van Ranst M, Van Wijngaerden E, Van-damme AM. Current Levels of Drug Resistance Among Therapy-Naive HIV-Infected Patients Have Significant Impact on Treatment Response. J Acquir Immune Defic Syndr. 2004;37:1664-1666
8. Oette M, Kaiser R, Daumer M, Akbari D, Fatkenheuer G, Rockstroh JK, Stechel J, Rieke A, Mauss S, Schmaloer D, Gobels K, Vogt C, Wettstein M, Haussinger D.. Primary drug-resistance in HIV-positive patients on initiation of first-line antiretroviral therapy in Germany. Eur J Med Res. 2004;9:273-8.
9. Blower SM, Aschenbach AN, Gershengorn HB, Kahn JO., Predicting the unpredictable: transmission of drug-resistant HIV. Nat Med. 2001;7:1016-20. Erratum in: Nat Med. 2003;9:146.
10. Berkhout B, de Ronde A, van der Hoek L. Aggressive HIV-1? Retrovirology. 2005;2:13.
11. Smith DM, Wong JK, Hightower GK, Ignacio CC, Koelsch KK, Petropoulos CJ, Richman DD, Little SJ. HIV drug resistance acquired through superinfection. AIDS. 2005; 12:1251-6.
12. Rosińska M, Werbińska-Sienkiewicz B. HIV infections and AIDS cases in Poland. In: National Institute of Hygiene, editor. Annual reports of National Institute of Hygiene, Warsaw, 2005
13. Lucas GM, Gallant JE, Moore RD. Relationship between drug resistance and HIV-1 disease progression or death in patients undergoing resistance testing. AIDS. 2004; 18:1539-48
14. Masquefier B, Costagliola D, Schmuck A, Cottalorda J, Schneider V, Izopet J Calvez V, Descamps D, Poggi C, Brun-Vezinet F; ANRS resistance sudy group. Prevalence of complete resistance to at least two classes of antiretroviral drugs in treated HIV-1-infected patients: a French nationwide study. J Med Virol. 2005;76:441-6
15. Pillay D, Green H, Mathias R, Dann D, Phillips A, Sabin C, Evans B; UK Collaborative Group on HIV Drug Resistance. Estimating HIV-1 drug resistance in antiretroviral-treated individuals in the United Kingdom. J Infect Dis. 2005;192:967-73
16. Miller MD, Margot NA, Hertogs K, Larder B, Miller V. Antiviral activity of tenofovir (PMPA) against nucleoside-resistant clinical HIV samples. Nucleosides Nucleotides Nucleic Acids. 2001;20:1025-8.
17. Durant J, Clevenbergh P, Halfon P, Delgiudice P, Porsin S, Simonet P Montagne N, Boucher CA, Schapiro JM, Dellamonica P. Drug-resistance genotyping in HIV-1 therapy: the VIRA-DAPT randomised controlled trial. Lancet. 1999; 26:2195-9
18. Baxter JD, Mayers DL, Wentworth DN, Neaton JD, Hoover ML, Winters MA Mannheimer SB, Thompson MA, Abrams DI, Brizz BJ, Ioannidis JP, Merigan TC. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS 2000;14:F83-93.
19. Servais J, Lambert C, Fontaine E, Plesseria JM, Robert I, Arendt V, Staub T, Schneider F, Hemmer R, Burtonboy G, Schmit JC.. Comparison of DNA sequencing and a line probe assay for detection of human immunodeficiency virus type 1 drug resistance mutations in patients failing highly active antiretroviral therapy. J Clin Microbiol 2001;39:454-9.
20. Horban A, Stanczak JJ, Bakowska E, Tobolewska EJ, Przybylska-Stengiel KJ, Stanczak GP, Burkacka E. High prevalence of genotypic resistance to Nucleoside Reverse Transcriptase Inhibitors among therapy-naïve individuals from the Warsaw cohort. Infection 2002; 30:356-9
21. Lipniacki A, Sheppard HW, Dondero DV, Piasek A and Horban A. Determination of HIV-1 subtypes in Polish patients using HMA method. Preliminary data. Sixth European Conference on Clinical Aspects and Treatment of HIV, Hamburg, 1997
22. Lukashov VV, Huismans R, Rakhmanova AG, Lisitsina ZN, Akhtyrskaya NA, Vlasov NN Melnick OB, Goudsmit J. Circulation of subtype A and gagA/envB recombinant HIV type 1 strains among injecting drug users in St. Petersburg, Russia, correlates with geographical origin of infections. AIDS Res Hum Retroviruses 1999; 15:1577-83
23. Stańczak JJ, Opoka-Kegler J, Czerwionka-Szaflarska M, Karczewska K, Woźniakowska-Gesicka T, Horban A. Distribution of hepatitis C virus genotypes in Poland. J Hepatol 1999, 31:574
24. Stańczak JJ, Tobolewska E, Przybylska-Stengiel K, Stańczak GP, Horban A. Changes in the pattern of Hepatitis c virus genotypes in Poland. ICVHLD Sydney, 2003
25. Buonaguro L, Tagliamonte M, Tornesello ML, Pilotti E, Casoli C, Lazzarin A, Tambussi G, Ciccozzi M, Rezza G, Buonaguro FM; Italian Concerted Action on PHI Treatment. Screening of HIV-1 isolates by reverse heteroduplex mobility assay and identification of non-B subtypes in Italy. J Acquir Immune Defic Syndr. 2004;37:1295-306